#NASDAQ #Bridgewater #Insmed #Inducement Awards

Insmed Grants Inducement Awards Under NASDAQ Rule 5635(c)(4)

Insmed Incorporated, a dedicated biopharmaceutical enterprise known for its people-first approach, recently disclosed that it has awarded inducement grants to 19 new employees. This initiative, in line with NASDAQ Listing Rule 5635(c)(4), was officially sanctioned by Insmed's Compensation Committee. The objective of these grants is to provide substantial incentives to the new hires while they embark on their journey with the organization.

Effective January 2, 2025, these new team members have been granted options to purchase a total of 65,930 shares of Insmed's common stock. The exercise price stands at $69.95 per share, corresponding to the closing trading price listed on the Nasdaq Global Select Market on that grant date.

The options granted to these employees come with a 10-year term along with a structured vesting system. Under this arrangement, 25% of the shares will vest on the first anniversary of the grant date, followed by subsequent vesting of 12.5% every six months thereafter until the four-year anniversary. This schedule is contingent upon the employees' continuing service with Insmed as of the respective vesting dates.

About Insmed

Insmed Incorporated is dedicated to transforming the lives of patients battling serious conditions through innovative therapies. The company manages a diversified array of approved and investigational medicines targeting significant unmet health needs, particularly in the domains of pulmonary and inflammatory diseases. One of its notable therapies has secured approvals in the United States, Europe, and Japan for treating a chronic lung ailment.

Furthermore, Insmed is engaged in advancing cutting-edge research across various technology platforms, including gene therapy and AI-driven approaches. Headquartered in Bridgewater, New Jersey, the organization extends its reach through research facilities and offices across the United States, Europe, and Japan. Its commitment to its workforce has positioned Insmed as a leading employer in the biopharmaceutical landscape, recognized as one of the top